Zaragoza

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease3 trials
• Stroke3 trials
• Familial hypercholesterolaemia2 trials
• Fatty liver disease (MASLD/MASH)1 trial
• Multiple sclerosis1 trial
• Psoriasis1 trial

Phase

• Phase 34 trials

Status

• Active, not recruiting3 trials
• Completed2 trials
• Recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals6 trials

Running trials

• Recruiting

  A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD

  NCT07683065· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)1 recruiting
• Psoriasis1 recruiting

Closed trials

• Completed

  A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice

  NCT06251986· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source